touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application.
The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- Could you tell us a little about the unique design and methodology of the COURAGE study? (0:14)
- What have the interim study findings shown about the efficacy of ubrogepant when used in combination with a mAb or with onabotulinumtoxinA? (1:37)
- How do you anticipate use of the Migraine Buddy app developing in the future? (3:12)
Disclosures: Richard Lipton reports receives research support from the NIH, FDA as well as the National Headache Foundation and the Marx Foundation; and also receives research support from Allergan/Abbvie, Amgen, Eli Lilly and Electrocore. Richard Lipton receives personal fees as a consultant or advisor from from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy’s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Novartis, Lundbeck, Merck, and Teva Pharmaceuticals; and holds stock or options in Biohaven Holdings and CtrlM Health.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Peter Goadsby, EAN 2023: Highlights in migraine
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) highlights two presentations from the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of migraine; the first by Klein et al. looking at a new potential biomarker of visual snow syndrome, and the second a presentation that he […]
Peter Goadsby, EAN 2023: Highlights in headache disorders
In this touchNEUROLOGY interview, editorial board member Prof Peter Goadsby (King’s college Hospital, London) provides an overview of his top three most important clinical trial data and hot topics presented at the annual European Academy of Neurology (EAN), July 1–4, 2023, in the field of headache disorders. He highlights two important presentations using calcitonin gene-related peptide […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!